Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07644559 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
A Phase 2 study, sponsored by Verastem.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT07644559: Recruiting Phase 2 study, sponsored by Verastem.
NCT07644559 is a Phase 2 study that is actively recruiting participants, run by Verastem. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07644559, a Phase 2 study, is actively recruiting participants, sponsored by Verastem.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Primary Outcome
Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR)
Interventions
- DRUG cetuximab
- DRUG VS-7375
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-06-16 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT07644559 shows while recruiting
NCT07644559 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 2 interventions - of which cetuximab is the first listed.
NCT07644559 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07644559 about?
NCT07644559 is a clinical study titled "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer". This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
What is the current status of trial NCT07644559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-06-16. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07644559?
The interventions under investigation include: cetuximab (DRUG), VS-7375 (DRUG).
Who is sponsoring clinical trial NCT07644559?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07644559's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI